Last reviewed · How we verify

HPV-16/18 vaccine — Competitive Intelligence Brief

HPV-16/18 vaccine (HPV-16/18 vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prophylactic vaccine. Area: Oncology / Immunology.

phase 3 Prophylactic vaccine HPV-16 and HPV-18 L1 capsid proteins Oncology / Immunology Biologic Live · refreshed every 30 min

Target snapshot

HPV-16/18 vaccine (HPV-16/18 vaccine) — Shanghai Zerun Biotechnology Co.,Ltd. This vaccine stimulates the immune system to produce antibodies and cellular immunity against human papillomavirus types 16 and 18, preventing infection and associated cancers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HPV-16/18 vaccine TARGET HPV-16/18 vaccine Shanghai Zerun Biotechnology Co.,Ltd phase 3 Prophylactic vaccine HPV-16 and HPV-18 L1 capsid proteins
Human Papillomavirus Human Papillomavirus Peking Union Medical College Hospital marketed Prophylactic vaccine Human Papillomavirus capsid protein (L1)
HPV vaccine HPV vaccine Fondazione IRCCS Policlinico San Matteo di Pavia marketed Prophylactic vaccine Human papillomavirus (HPV) capsid proteins / L1 antigen
Recombinant Human Papillomavirus Bivalent Vaccine Recombinant Human Papillomavirus Bivalent Vaccine National Cancer Institute (NCI) marketed Prophylactic vaccine Human papillomavirus types 16 and 18 (HPV-16, HPV-18)
Flu Vaccine Flu Vaccine La Fundacion Favaloro para la Investigacion y la Docencia Medica marketed Prophylactic vaccine Influenza A and B viral hemagglutinin and neuraminidase surface antigens
Licensed quadrivalent HPV vaccine, Gardasil Licensed quadrivalent HPV vaccine, Gardasil Murdoch Childrens Research Institute phase 3 Prophylactic vaccine Human papillomavirus (HPV) types 6, 11, 16, 18
HPV-16/18 L1 VLP AS04 HPV-16/18 L1 VLP AS04 GlaxoSmithKline phase 3 Prophylactic vaccine HPV-16 and HPV-18 L1 capsid protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prophylactic vaccine class)

  1. GlaxoSmithKline · 5 drugs in this class
  2. La Fundacion Favaloro para la Investigacion y la Docencia Medica · 1 drug in this class
  3. Fondazione IRCCS Policlinico San Matteo di Pavia · 1 drug in this class
  4. National Cancer Institute (NCI) · 1 drug in this class
  5. Peking Union Medical College Hospital · 1 drug in this class
  6. Shanghai Zerun Biotechnology Co.,Ltd · 1 drug in this class
  7. Murdoch Childrens Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HPV-16/18 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/hpv-16-18-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: